Endomyocardial biopsy safety and clinical yield in pediatric myocarditis: An Italian perspective
Authors:
- Maurizio BrighentiMBMaurizio Brighenti
- Maria Giulia GagliardiMaria Giulia Gagliardi
- Nicola MaschiettoNMNicola Maschietto
- Davide MariniDMDavide Marini
- On Behalf Of The Italian Society Of Pediatric CardiologyOCOn Behalf Of The Italian Society Of Pediatric Cardiology
- 29 October 2015
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 87 (4) , 762-767
Abstract
Objectives: The objective of this investigation is to evaluate the safety, the impact of endomyocardial biopsy (EMB) results in myocarditis management and the incidence of different etiologies of myocarditis in a pediatric population.Background: Although EMB is an established diagnostic tool to evaluate suspected myocarditis, there is lack of clear diagnostic and management guidelines for myocarditis in pediatric patients, particularly in infants.Methods: We performed a retrospective database review and subsequent outcomes analysis from five Italian pediatric cardiology centers to identify patients aged 0–18 years who underwent EMB for suspected myocarditis or inflammatory cardiomyopathy (ICMP) between 2009 and 2011.Results: EMB was performed in 41 children, of which 16 were male. The population ranged between 16 days of age to 17 years (mean age at EMB = 5.2 ± 4.9 years). The overall incidence of EMB‐related complications was 15.5% (31.2% in infants, and 6.8% in children > 1 year of age; P = 0.079) while the incidence of EMB‐driven treatment changes was 29.2%. Histological examination together with PCR on heart biopsy specimens allowed an etiological diagnosis in 26/41 patients (63%). Among the 15 patients (36.5%) with diagnosis of dilated cardiomyopathy (DCM) 11 had idiopathic DCM. Finally, we found an overall incidence of death/cardiac transplantation of 24%.Conclusions: In a pediatric population with suspected myocarditis/ICMP, EMB was useful in confirming the diagnosis only in 41% of cases but showed an overall diagnostic power of 63%. As complications of EBM are not negligible, particularly in infants, the risk/benefit ratio should be taken into account in each patient.Keywords
This publication has 17 references indexed in Scilit:
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2013
- A 25‐year experience of endomyocardial biopsy safety in infantsCatheterization and Cardiovascular Interventions, 2013
- Demographics, Trends, and Outcomes in Pediatric Acute Myocarditis in the United States, 2006 to 2011Circulation: Cardiovascular Quality and Outcomes, 2012
- 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular PathologyCardiovascular Pathology, 2012
- Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: Results of a multicenter experienceThe Journal of Heart and Lung Transplantation, 2012
- MyocarditisThe Lancet, 2012
- Routine Performance of Endomyocardial Biopsy Decreases the Incidence of Orthotopic Heart Transplant for MyocarditisThe Journal of Heart and Lung Transplantation, 2009
- The Role of Endomyocardial Biopsy in the Management of Cardiovascular DiseaseCirculation, 2007
- Complications of endomyocardial biopsy in childrenJACC, 1999
- Association of Parvovirus B19 Genome in Children With Myocarditis and Cardiac Allograft RejectionCirculation, 1997